Profile data is unavailable for this security.
About the company
BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.
- Revenue in ILS (TTM)43.14m
- Net income in ILS-181.90m
- Incorporated2003
- Employees79.00
- LocationBioline Rx LtdModi'in Technology Park2 HaMa'ayan StreetMODIIN 7177871IsraelISR
- Phone+972 86429100
- Fax+972 86429101
- Websitehttps://www.biolinerx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nextage Therapeutics Ltd | 1.02m | -3.36m | 27.56m | -- | -- | -- | -- | 26.97 | -0.1057 | -0.1057 | 0.032 | -0.1293 | 1.58 | -- | 10.32 | -- | -553.86 | -188.94 | -- | -423.76 | 22.60 | 33.33 | -351.17 | -2,486.19 | -- | -65.46 | -- | -- | -- | 17.99 | 30.57 | -- | -- | -- |
| Kadimastem Ltd | 0.00 | -9.68m | 53.30m | 32.00 | -- | -- | -- | -- | -2.12 | -2.12 | 0.00 | -1.94 | 0.00 | -- | -- | -- | -129.59 | -155.33 | -- | -1,831.12 | -- | -- | -- | -- | -- | -3.11 | 3.31 | -- | -- | -- | 47.14 | -- | -50.73 | -- |
| Matricelf Ltd | 0.00 | -13.66m | 63.81m | -- | -- | 2.96 | -- | -- | -0.8738 | -0.8738 | 0.00 | 1.34 | 0.00 | -- | -- | -- | -47.15 | -- | -50.89 | -- | -- | -- | -- | -- | -- | -- | 0.057 | -- | -- | -- | -10.77 | -- | -- | -- |
| X T L Biopharmaceuticals Ltd | 1.68m | -83.24m | 80.87m | 33.00 | -- | 0.4222 | -- | 48.13 | -0.378 | -0.378 | 0.0076 | 0.1527 | 0.0192 | -- | 0.7012 | 50,918.16 | -94.96 | -53.17 | -111.98 | -59.10 | -- | -2.33 | -4,953.75 | -1,084.42 | -- | -- | 0.00 | -- | -85.80 | -- | -7.97 | -- | -53.12 | -- |
| DNA Group TR Ltd | 306.00k | 15.05m | 110.60m | 14.00 | 7.35 | 1.13 | -- | 361.44 | 0.1222 | 0.1222 | 0.0025 | 0.7981 | 0.0033 | -- | 1.44 | 21,857.14 | 16.35 | -23.54 | 16.48 | -26.27 | -- | -- | 4,918.63 | -7,406.24 | -- | -- | 0.00 | -- | -45.36 | -- | 95.00 | -- | -- | -- |
| BioLine RX Ltd | 43.14m | -181.90m | 127.34m | 79.00 | -- | 2.39 | -- | 2.95 | -0.1882 | -0.1882 | 0.043 | 0.0445 | 0.1939 | -- | 6.40 | 546,029.40 | -81.75 | -52.74 | -127.94 | -65.43 | 55.84 | -- | -421.69 | -3,501.79 | 1.05 | -519.43 | 0.4642 | -- | -- | -- | -142.93 | -- | -50.72 | -- |
| Bonus Biogroup Ltd | 0.00 | -29.19m | 134.31m | 58.00 | -- | 8.72 | -- | -- | -0.0718 | -0.0718 | 0.00 | 0.0132 | 0.00 | -- | -- | 0.00 | -64.14 | -76.10 | -74.97 | -97.19 | -- | -- | -- | -- | -- | -- | 0.4106 | -- | -- | -- | 26.29 | -- | 19.30 | -- |
| Compugen Ltd | 221.52m | 5.92m | 467.25m | 68.00 | 74.70 | 2.12 | -- | 2.11 | 0.071 | 0.071 | 2.48 | 2.50 | 0.6263 | -- | 24.50 | 3,257,621.00 | 1.67 | -28.41 | 2.09 | -32.57 | 84.53 | 92.40 | 2.67 | -293.48 | -- | -- | -- | -- | 346.12 | 13.45 | 44.34 | -- | 1.71 | -- |
Data as of Nov 25 2024. Currency figures normalised to Bioline Rx Ltd's reporting currency: Israeli Shekel ILS
0.08%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Dimensional Fund Advisors LPas of 07 Nov 2024 | 675.09k | 0.06% |
| Dimensional Fund Advisors Ltd.as of 31 Aug 2024 | 302.84k | 0.03% |
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
